Verve Therapeutics (NASDAQ:VERV – Get Free Report) and ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.
Risk & Volatility
Verve Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Profitability
This table compares Verve Therapeutics and ANI Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Verve Therapeutics | -1,226.51% | -37.35% | -29.31% |
ANI Pharmaceuticals | 6.87% | 17.15% | 8.29% |
Insider & Institutional Ownership
Analyst Recommendations
This is a summary of current ratings and price targets for Verve Therapeutics and ANI Pharmaceuticals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Verve Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
ANI Pharmaceuticals | 0 | 1 | 3 | 0 | 2.75 |
Verve Therapeutics currently has a consensus price target of $30.40, suggesting a potential upside of 509.22%. ANI Pharmaceuticals has a consensus price target of $82.75, suggesting a potential upside of 42.92%. Given Verve Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Verve Therapeutics is more favorable than ANI Pharmaceuticals.
Valuation & Earnings
This table compares Verve Therapeutics and ANI Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Verve Therapeutics | $16.05 million | 26.11 | -$200.07 million | ($2.87) | -1.74 |
ANI Pharmaceuticals | $538.95 million | 2.25 | $18.78 million | $1.60 | 36.19 |
ANI Pharmaceuticals has higher revenue and earnings than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
About Verve Therapeutics
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.